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“Click” reactions have become very common and powerful ligation techniques, of which 1,3-dipolar
cycloadditions have most frequently been employed. Since metal-mediated cycloadditions are
incompatible in biomedical applications due to toxicity issues associated with transition metals like
copper, metal-free variants provide important alternatives. The metal-free conjugation process is studied
in detail with special emphasis put on the reaction progress. This report unfolds the ﬁrst aqueous metal-
free “click” conjugation of a cyclic RGD-pentapeptide with the biomacromolecule alginate, creating a
“smart” bioactive polymer with potential applications in biomedicine.
Introduction
The last decade has seen the development of powerful synthetic
methods to link or merge biomolecules with each other or other
complex molecular entities. Terms like “click” reactions and
chemical ligation are associated with this chemistry that has
paved the way to speciﬁcally modify complex biological systems
at will.1 In this context, the preparation of peptide–polymer bio-
conjugates is a very important issue that can be realised by
“grafting onto” or by “grafting from” approaches.2 The most
popular “grafting to” technique is the copper-mediated Huisgen-
type 1,3-dipolar cycloaddition, ﬁrst reported by Meldal and
Sharpless, respectively.3 This azido–alkyno cycloaddition is a
versatile bioconjugation strategy as both functionalities react
chemoselectively, while being rare or not present in nature.
These so-called bioorthogonal reactions are insensitive to func-
tional groups in biological systems.4 As a consequence, “click”
reactions are widely employed in biological and biomedical
systems.5 However, metal-catalyzed ligations are not well-suited
due to toxicity issues which resulted in the development of
several metal-free alternatives6 that even work in aqueous
media.7 The best studied dipolar cycloadditions within this ﬁeld
rely on cyclooctyne as well as oxanorbornadiene derivatives.8
Our approach for decorating biopolymers with bioactive pep-
tides requires components that are soluble in aqueous media
which is guaranteed by Rutjes’ oxanorbornadiene approach.9,10
Indeed, this strategy serves multiple aspects for a biocompatible
ligation: (i) solubility and reactivity under aqueous conditions,
(ii) reaction progress at room temperature, (iii) no additives or
catalysts required and (iv) formation of readily removable bypro-
ducts. The high reactivity and chemoselectivity of the oxanor-
bornadiene unit is associated with the vinylic CF3-substituted
oleﬁn, which can undergo Huisgen-cycloadditions with 1,3-
dipoles such as azides. Moreover, volatile furan is released as a
by-product forcing the equilibrium towards product formation.9
We utilised Rutjes’ method to modify the polysaccharide algi-
nate with a cyclic RGD-pentapeptide for potential applications in
regenerative medicine (Scheme 1). Due to speciﬁc interactions
with integrins on the cell membrane, cyclic RGD-oligopeptides
promote the adhesion of cells,11 including stem cells.12 To the
best of our knowledge, we report the ﬁrst metal-free ligation of
these kinds of peptides with a biopolymer by using a metal-free
1,3-dipolar cycloaddition approach. In order to study the oxanor-
bornadiene mediated conjugation in detail we chose a model
reaction with azido-valeric acid, both for the ligation on the
polymeric as well as for the monomeric model level. 1H- and
19F-NMR spectroscopy served as a primary analytical tool. In
detail, 19F-NMR spectroscopy allowed us to identify the triazole
linkages formed, while 1H-NMR spectroscopy was suited to
determine the progress of the reaction. In our hands, 19F-NMR
spectroscopy is generally applicable to detect and characterise
Scheme 1 Structures of alginate 1 and azido-derivatised cyclic RGD-
pentapeptide 2.
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these ﬂuoro-substituted triazoles, even when formed on
polymers.
Results and discussion
Preparation of oxanorbornadiene functionalised alginate 5
Using a slightly modiﬁed preparation with respect to Rutjes and
co-workers9 bicycle 313 was transformed into the amino deriva-
tive 4 and attached to the carboxylate moiety of alginate 1
(Scheme 2).
Oxanorbornadiene modiﬁed alginate 5 was prepared under
classical active-ester conditions in an alkaline, aqueous medium.
Depending on the added amount of 4, the degree of functionali-
sation could be adjusted between 30% and 70%. Analysis of 5
was based on 1H- and 19F-NMR spectroscopy.14
The opportunity to adjust the degree of functionalisation in a
variable manner is important from a biomedical point of view as
it allows us to directly adjust the amount of the alginate bound
RGD-peptide. The degree of decoration can either be controlled
by the number of oxanorbornadiene functionalities present on
the polymer or by the amount of azido cRGD-pentapeptide
added. As the “click” process does not require additives, excess
of unbound azido-conjugates can be simply regained after
dialyses.
Preparation of alginate conjugates
Next, three azides, namely valeric acid derivative 6, Boc-pro-
tected azido-lysine 716 and azido-cRGD-pentapeptide 2,15 were
fused with functionalised alginate 5 in aqueous media, yielding
decorated alginates 8–10 (Scheme 3). Again, the successful
ligation as well as the degree of decoration were proven by 1H-
and 19F-NMR spectroscopy in D2O.
14 The ﬁrst two azides 6 and
7 served as model compounds for optimising the cycloaddition
conditions as well as for establishing the analytical basis of this
ligation process.
Due to its low solubility in aqueous solutions azido-cRGD-
pentapeptide 215 had to be added in sub-stoichiometric amounts.
To prevent precipitation of the ligation product, polysaccharide 5
with a low degree of derivatisation (∼30%) was used. With
intense stirring, the mixture was allowed to react for 4 days in
the dark. After dialyses and lyophilisation cRGD modiﬁed
alginate 8 was collected. To the best of our knowledge, this is
the ﬁrst example of a metal-free conjugation of cRGD-peptide to
a biopolymer alginate under physiologically compatible
conditions.
In the case of 7, only 0.5 equiv. of the azide derivative were
added to alginate 5. 19F-NMR and 1H-NMR analysis of this
experiment showed that the expected amount of oxanorborna-
diene was consumed and coupled, which in principle paves the
way for a stepwise decoration using a second azide.
Detailed study of the ligation
The progress of cycloaddition was studied by 1H-NMR, while
19F-NMR spectroscopy was used to quantify and identify the
nature of the cycloaddition products. It has to be stressed that the
metal-free oxanorbornadiene cycloaddition generates two regio-
isomeric triazoles while furan is formed as a volatile byproduct.9
Furan formation was used to monitor the progress of the cyclo-
addition and the degree of transformation (Fig. 1a). Simulta-
neously the oxanorbornadiene unit disappears and both
processes served to track the reaction by 1H-NMR spectroscopy
using the signal at δ = 2.8 ppm (referring to remaining EDC) for
calibration (Fig. 1b and 1c). In the case of 5-azido valeric acid 6
the cycloaddition was monitored over 29 h (Fig. 1b). As can be
seen the integrals hardly changed after 25 h, indicating the end
of the cycloaddition and almost complete transformation. As the
furan by-product is rather volatile it could not serve for exact
quantiﬁcation.
When cRGD-pentapeptide 2 was added in sub-stoichiometric
amounts, expectedly residual oxanorbornadiene signals originat-
ing from 5 could still be detected (Fig. 1c). Using 0.5 equiv. of
cRGD-pentapeptide 2 the reaction was ﬁnished after 4 days
when no further increase of furan formation was measured. Com-
pared to azido-valeric acid 6 the reaction of cRGD 2 took twice
as long, indicating the increased steric demand of the cRGD-
pentapeptide as well as its lower water-solubility.
In their reports, Rutjes et al.9 provided a detailed analysis of
the cycloaddition that commonly provides two regioisomers
(here named cis/trans; Scheme 4, path A). Additionally, they
Scheme 2 Synthesis of functionalised alginate 5.
Scheme 3 Metal-free cycloaddition of azido-cRGD 2, 5-azido valeric
acid 6 and Boc-protected ε-azido-lysine 7 yielding triazoles 8–10 (cis
and trans refer to triazole regioisomers).
















































identiﬁed another by-product, a triﬂuoromethylfuran, that must
have resulted from an alternative chemoselective azide-initiated
cycloaddition with the second oleﬁn (Scheme 4, path B). In prin-
ciple, this side reaction can be minimised, when methyl-substi-
tuted oxanorbornadienes are employed.10b In the present case,
non-polymeric compounds such as 11 which are formed via
pathway B can advantageously be removed by dialyses. Still, the
triﬂuoromethylfuran moiety, represented as 12, is expected to
remain at the alginate backbone.
However, 1H-NMR spectroscopy does not allow us to identify
the regio- and chemoisomers which are formed upon cyclo-
addition so we chose 19F-NMR spectroscopy for detecting the
triﬂuoromethyl groups of the different isomers present on the
biopolymer (Fig. 2a–c).
Functionalised alginate 5 gave a 19F-NMR signal for the CF3
moiety at δ = −62.5 ppm (Fig. 2a). The cycloaddition of azides
6 and 7 resulted in decorated polymers that revealed a new set of
19F signals (Fig. 2b and 2c). The signal at δ = −62.5 ppm com-
pletely disappeared when an equimolar amount of 6 with respect
to oxanorbornadiene units on alginate was added (Fig. 2b). Sub-
stoichiometric amounts of added azide 7 expectedly resulted in
incomplete conversion (Fig. 2c). Nevertheless in both cases the
same additional signal pattern was found. Likewise, conjugation
of cyclic RGDfK-peptide 2 with alginate 5 gave a similar set of
19F signals14 that only showed marginal chemical shift difference
to the ligation products resulting from azide 7. Speciﬁcally,
polymer bound ligation products 9 and 10 (Fig. 2b and 2c)
revealed new 19F-data at −56.3 ppm (35%) and two signals at
−59.1 ppm and −59.3 ppm, respectively, with reduced intensi-
ties (together 55%). In addition, a fractional signal at −56.8 ppm
(10%) was detected.
As mentioned before, it was not possible to conduct a detailed
analysis with these biomacromolecules. Therefore, we prepared
model compounds that reﬂect the mode of cycloaddition pro-
ducts and would help to elucidate the chemical environment of
the 19F signals detected on alginates 8–10. We chose the mono-
saccharide galacturonic acid as an adequate model compound.
Methyl-(allyl-β-D-galactopyranoside)uronate 13 was prepared
according to Voss et al.17 Joining the oxanorbornadiene 4 with
galacturonic acid 13 was accomplished by ﬁrst saponiﬁcation
which was followed by coupling under standard conditions.
Compound 14 was collected after preparative HPLC puriﬁcation.
In order to clarify the polymer ligation data, 5-azido valeric acid
6 was reacted with 14 under aqueous conditions as described
above for alginate (Scheme 5). The cycloaddition products 15a
and 15b were separated by preparative HPLC and characterised14
using different NMR techniques (1H-, 13C-, HSQC-, HMBC-
and 19F-NMR).
The chemical shifts for the 19F-NMR signals in 5-triﬂuoro-
methyl-1,2,3-triazole 15a (δ = −56.3 ppm, cis regioisomer;
Fig. 2d) and in 4-triﬂuoromethyl-1,2,3-triazole 15b (δ =
−59.3 ppm, trans regioisomer; Fig. 2e) differed signiﬁcantly and
can favourably be assigned to the signals of the ligation products
9 and 10 (Fig. 2b and 2c). The broader signals observed for the
polymer samples are due to longer relaxation times associated
with coiled macromolecular backbone structures.
In order to elucidate the nature of the remaining signals
(Fig. 2b and 2c) we prepared a second model compound 20 that
represents the furan moiety 12 of the undesired pathway B
(Scheme 4).9 The appropriate model compound 20 was prepared
in four steps (Scheme 6). Starting from oxanorbornadiene 16,
furan 18 was synthesised by a [4 + 2] Diels–Alder cyclo-
addition–cycloreversion sequence between 16 and tetraphenyl-
cyclopentadienone 17.18 As byproducts, carbon monoxide and
tetraphenylbenzene are formed. Triﬂuoromethyl-substituted
furan 18 was ﬁrst saponiﬁcated followed by amide formation
with N-Boc-ethylendiamine and Boc-deprotection to yield the
target furan 20 soluble in aqueous media.
19F-NMR spectroscopic analysis of furan 20 displayed a
signal at δ = −59.1 ppm in D2O. Obviously, the chemical shifts
of the triﬂuoromethyl group in the unfavoured furan by-product
and (trans)-regioisomer 15b are very similar. Thus, close inspec-
tion of the 19F signals in modiﬁed alginates 9 and 10 reveals
ﬂanking peaks around δ = −59 ppm (Fig. 2b and 2c). Signal
intensities indicate that route B becomes less neglectable when
Fig. 1 (a) Ligation progress over time monitored by 1H-NMR spec-
troscopy (staggered arrangement) exempliﬁed for 5-azido valeric acid 6:
formation of furan (increasing signals) and simultaneous disappearance
of an oxanorbornadiene system (decreasing signals). (b) Ligation of 6:
conversion over time; (c) ligation of 2: conversion over time.
















































switching from solution chemistry to cycloadditions of polymer-
bound oxanorbornadiene with azides. Apparently, steric conges-
tion and folding of the polymer backbone do affect the accessi-
bility of both oleﬁnic groups in the oxanorbornadiene system.
Thus, formation of undesired cycloaddition products of type
12 cannot be completely avoided in the case of polymer conju-
gation. Finally, at this point the chemical environment of the
remaining 19F-NMR signal at δ = −56.8 ppm (Fig. 2b and 2c)
could not be elucidated.
Conclusions
In summary, we developed a synthetic route for the successful
conjugation of cRGD-pentapeptides to modiﬁed alginate by
employing a metal-free 1,3-dipolar cycloaddition approach. The
ligation proceeded within 3 days at room temperature in aqueous
media. The procedure relies on the initial implementation of the
oxanorbornadiene which was followed by a mild, bioorthogonal
cycloaddition. Progress of alginate decoration was monitored by
Scheme 4 Regular cycloaddition provides two regioisomeric triazoles (path A, represented by substructures 9 and 10); uncommon cycloaddition
with an alternative alkene moiety results in the formation of by-products (path B, represented by substructures 11 and 12) as proposed by Rutjes et al.
for a non-polymeric system.9
Fig. 2 19F-NMR spectroscopic data of (a) starting material 5; (b)
addition of 1.0 equiv. 6; (c) addition of 0.5 equiv. 7; (d) galacturonic
acid cis-triazole 15a; (e) galacturonic acid trans-triazole 15b; (f ) furan
derivative 20.
Scheme 5 Synthesis of galacturonic acid derivatives 15a and 15b.
Scheme 6 Synthesis of model compound 20.
















































1H-NMR and 19F-NMR spectroscopy. Model compounds were
synthesised to evaluate the regio- and chemoselectivity of the
cycloaddition that yielded substituted triazoles. So far, this is the
ﬁrst study to analytically follow metal-free “click”-reactions con-
ducted with a biomacromolecule. Finally, the feasibility of a
macromolecular metal-free ligation under physiological con-
ditions was proven. Future studies will be directed to develop
RGD-modiﬁed hydrogels based on different biomacromolecules
and study their biocompatibility in the context of regenerative
therapies and tissue engineering.
Experimental
General remarks
Unless otherwise stated, all chemicals and solvents were pur-
chased in per analysis quality and used as received. All dialysis
steps were performed using Visking membrane tubes (regene-
rated cellulose, 0.025 mm membrane thickness, 28.6 mm dia-
meter, obtained from Roth, Karlsruhe, Germany) with a
molecular weight cut-off of 14 000 g mol−1. All modiﬁed poly-
mers were exhaustively dialysed for 3 to 5 days against distilled
water. Lyophilisation was performed with a Christ Alpha 2–4
(Christ, Osterode, Germany) freeze dryer. Melting points (Mp)
were determined with an MPA100 OptiMelt instrument
(Stanford Research Systems). 1H NMR spectra were recorded at
400 MHz and 13C NMR spectra were recorded at 100 MHz with
a BRUKER Avance-400. 19F-NMR spectra were recorded with a
BRUKER Avance-III-600. Chemical shift values of NMR data
are reported as values in ppm relative to (residual undeuterated)
the solvent signal as an internal standard. Multiplicities for
1H NMR signals are described using the following abbrevi-
ations: s = singlet, d = doublet, t = triplet, q = quartet, m = multi-
plet; where appropriate with the addition of b = broad.
13C Multiplicities refer to the resonances in the off-resonance
decoupled spectra and were elucidated using the distortionless
enhancement by the polarisation transfer (DEPT) spectral editing
technique. Multiplicities for 13C NMR signals are reported using
the following abbreviation: q = quartet (CF3). For interpretation
of the triazole regioisomers (1H–13C correlations) phase-sensitive
HSQC and HMBC experiments were performed. Mass spectra
were obtained with a type LCT (ESI) (Micromass) equipped
with a lockspray dual ion source in combination with a Waters
Alliance 2695 LC system, or with a type Q-TOF premier (Micro-
mass) spectrometer (ESI mode) in combination with a Waters
Acquity UPLC system equipped with a Waters BEH C18 1.7 μm
column (solvent A: water + 0.1% (v/v) formic acid; solvent B:
MeOH + 0.1% (v/v) formic acid; ﬂow rate = 0.4 mL min−1;
gradient (t [min]/solvent B [%]): (0 : 5) (2.5 : 95) (6.5 : 95)
(6.6 : 5) (8 : 5)). Ion mass signals (m/z) are reported as values in
atomic mass units.
Synthesis of the ethylendiamine extended oxanorbornadiene-
system (4). Based on the results of Rutjes and co-workers9 a
modiﬁed synthesis of 3-triﬂuoromethyl-7-oxa-bicyclo[2.2.1]-
hepta-2,5-diene-2-carboxylic acid 3 was published by Dräger
and co-workers.13
tert-Butyl [2-(-3-(triﬂuoromethyl)-7-oxabicyclo[2.2.1]hepta-
2,5-diene-2-carboxamido)ethyl]carbamate (3a). 3 (100 mg,
0.481 mmol, 1.0 equiv.) and N-Boc-ethylendiamine HCl
(75.8 μL, 0.481 mmol, 1.0 equiv.) were dissolved in 1 mL of dry
methylene chloride under an argon atmosphere at 0 °C.
4-Dimethylaminopyridine (117.5 mg, 0.962 mmol, 2.0 equiv.)
and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochlo-
ride (101.1 mg, 0.529 mmol, 1.1 equiv.) were added and the
reaction mixture was stirred overnight at rt. The mixture was
washed with brine, the layers were separated and the organic
layer was dried over MgSO4. After puriﬁcation by column
chromatography (petroleum ether–ethyl acetate = 1 : 1) 3a was
isolated as a yellowish solid (102.3 mg, 293.9 μmol, 61%). Mp:
145 °C; Rf = 0.45 (PE–EtOAc: 1 : 1); δH (400 MHz, CDCl3)
7.37 (dd, J 5.3, J 1.9, 1H), 7.17 (dd, J 5.1, J 1.7, 1H), 6.66 (bs,
1H), 5.65–5.64 (m, 1H), 5.62–5.62 (m, 1H), 4.86 (bs, 1H),
3.51–3.41 (m, 1H), 3.35–3.29 (m, 1H), 1.46 (s, 9H); δC
(100 MHz, CDCl3) 162.7, 157.0, 154.1 (q, JC,F 4.9), 143.8 (q,
JC,F 36.3), 143.8, 142.2, 122.2 (q, JC,F 268.4), 86.2, 83.7 (t, JC,F
2.3), 80.2, 41.3, 40.0, 28.5; MS (ESI+): m/z 371.12 [M + Na]+,
calcd for C15H19F3N2O4Na 371.12.
N-(2-Aminoethyl)-3-(triﬂuoromethyl)-7-oxabicyclo[2.2.1]hepta-2,
5-diene-2-carboxamide (4). To a solution of 3a (6.0 mg,
17.2 mmol, 1.0 equiv.) in 1 mL of methylene chloride, triﬂuoro-
acetic acid was added (TFA, 60 μL, excess) successively and
stirred for 1 h. All solvents were removed by repeated azeotropic
distillation with toluene under reduced pressure. Finally, 4 was
isolated as a colourless solid (4.3 mg, 17.2 mmol, quant.). Mp:
155 °C; δH (400 MHz, CD3OD) 7.33 (dd, J 5.3, J 1.9, 1H), 7.25
(dd, J 5.3, J 1.9, 1H), 5.70–5.69 (m, 1H), 5.64–5.63 (m, 1H),
3.66–3.59 (m, 1H), 3.53–3.46 (m, 1H), 3.11 (dt, J 6.3, J 2.7,
2H); δC (100 MHz, CD3OD) 166.0, 155.8 (q, JC,F 5.1), 145.9
(q, JC,F 36.9), 144.6, 143.67, 123.76 (q, JC,F 267.7), 87.1, 84.6
(t, JC,F 2.2), 40.5, 38.34; MS (ESI
+): m/z 249.08 [M + H]+, calcd
for C10H12F3N2O2 249.08.
Oxanorbornadiene functionalised alginate (5). Sodium algi-
nate 1 (0.1 g, 0.51 mmol, 1.0 equiv., very low viscosity, ABCR,
Germany) was dissolved to homogeneity in 10 mL of H2Odist.
yielding a 1% (w/v) solution. Diisopropylethylamine (166 μL,
1.01 mmol, 2.0 equiv.), 1-hydroxybenzotriazole-hydrate
(78.0 mg, 0.51 mmol, 1.0 equiv.) and 1-(3-dimethylaminopro-
pyl)-3-ethylcarbodiimide hydrochloride (146.1 mg, 0.76 mmol,
1.5 equiv.) were added and the reaction mixture was stirred for
1 h. Then, 4 (151.7 mg, 0.61 mmol, 1.2 equiv.) was added and
the solution was stirred at room temperature overnight. In order
to precipitate the polymer, the aqueous solution was added drop-
wise to 20 mL of ethanol. After complete settling of the solid,
the colourless polymer was ﬁltered off, dissolved in water and
puriﬁed by dialysis against H2Odist. for 4 days. The water was
exchanged three times a day. After lyophilisation polymer 5 was
collected as a colourless, ﬂuffy material (115 mg). δH (400 MHz,
D2O) 7.28–7.26 (m, 2H), 5.86 (s, 1H), 5.73 (s, 1H), 4.13–3.56
(m, alginate), 3.43–3.02 (m, 4H); δF (600 MHz, D2O) −62.5.
Azido-cRGDfK conjugated to oxanorbornadiene functiona-
lised alginate (8). Oxanorbornadiene functionalised alginate 5
(10.0 mg, 0.025 mmol, 1.0 equiv., 30% derivatisation rate) was
dissolved to homogeneity in 3 mL of H2Odist.. Azido-cRGDfK 2
(7.8 mg, 12.5 μmol, 0.5 equiv.) was added and the reaction
mixture was stirred for 4 days in the dark. Then, the reaction
















































mixture was directly dialysed against H2Odist. for 4 days with
repeated water exchange (3× per day). After lyophilisation a
colourless, ﬂuffy material 8 was isolated (4 mg). δH (400 MHz,
D2O) 7.32–7.15 (m, 2H), 4.13–3.56 (m, alginate), 3.43 (s, 2H),
3.29 (s, 2H), 1.61–0.88 (m, 6H); δF (600 MHz, D2O) −56.1,
−56.8, −57.5, −62.3.
5-Azidovaleric acid conjugated to oxanorbornadiene functio-
nalised alginate (9). Oxanorbornadiene functionalised alginate 5
(10.0 mg, 0.025 mmol, 1.0 equiv., 70% derivatisation rate) was
dissolved to homogeneity in 3 mL of H2Odist.. 5-Azido valeric
acid 6 (3.5 mg, 0.026 mmol, 1.0 equiv.) was added and the reac-
tion mixture was stirred for 1 day in the dark. Then, the reaction
mixture was directly dialysed against H2Odist. for 4 days with
repeated water exchange (3× per day). After lyophilisation
polymer 9 was collected as a colourless, ﬂuffy material (6 mg).
δH (400 MHz, D2O) 4.60–4.53 (m, 2H, 9b), 4.49–4.43 (m, 2H,
9a), 4.13–3.65 (m, alginate), 3.48–3.43 (m, 2H), 3.06–3.04 (m,
2H), 2.31–2.22 (m, 2H), 1.92–1.79 (m, 2H), 1.57–1.43 (m, 2H);
δF (600 MHz, D2O) −56.2 (9a), −56.8, −59.1 (12), −59.2 (9b).
ε-Azido-Boc-lysine conjugated to oxanorbornadiene functio-
nalised alginate (10). Oxanorbornadiene functionalised alginate
5 (10.0 mg, 0.025 mmol, 1.0 equiv., 70% derivatisation rate)
was dissolved to homogeneity in 3 mL of H2Odist.. Azido-Boc-
lysine 7 (3.4 mg, 0.013 mmol, 0.5 equiv.) was added and the
reaction mixture was stirred for 2 days in the dark. Then, the
reaction mixture was directly dialysed against H2Odist. for 4 days
with repeated water exchange (3× per day). After lyophilisation
polymer 10 was collected as a colourless, ﬂuffy material (7 mg).
δH (400 MHz, D2O) 7.29–7.26 (m, 2H), 5.85 (s, 1H), 5.74 (s,
1H), 4.65–4.60 (m, 2H, 10b), 4.55–4.50 (2H, m, 10a),
4.17–3.66 (m, alginate), 3.63–3.19 (m, 8H), 3.14 (m, 2H),
1.93–1.85 (m, 2H), 1.63–1.59 (m, 2H), 1.40 (s, 9H); δF
(600 MHz, D2O) −56.1 (10a), −56.8, −59.1 (12), −59.2 (10b),
−62.3 (5).
(Allyl-β-D-galactopyranoside) uronic acid (13a). Methyl-
(allyl-β-D-galactopyranoside) uronate 13 was prepared according
to Voss et al.17 0.1 g of 13 (0.40 mmol, 1.0 equiv.) was dissolved
in 5 mL H2Odist. and ∼2 mL 1 M LiOHaq (2.02 mmol, 5.0
equiv.) were added until an alkaline pH was obtained. After stir-
ring for 12 h at room temperature, the reaction mixture was neu-
tralised using 1 M HClaq. A mixture of colourless crystals,
monosaccharides and LiCl was isolated after lyophilisation
(120 mg). δH (400 MHz, D2O) 6.04–5.94 (m, 1H), 5.38 (dd,
J 17.3, J 1.5, 1H), 5.27 (dd, J 9.9, J 0.7, 1H), 4.46–4.41 (m,
1H), 4.43 (d, J 7.8, 1H), 4.24–4.19 (m, 1H), 4.22 (dd, J 0.7,
J 4.1, 1H), 4.12 (d, J 1.4, 1H), 3.68 (dd, J 9.9, J 3.4, 1H), 3.53
(dd, J 9.9, J 7.85, 1H); δC (100 MHz, D2O) 174.4, 133.5, 118.8,
101.2, 75.2, 72.9, 70.4, 70.3, 70.0; MS (ESI−): m/z 233.07
[M − H]−, calcd for C9H13O7 233.06.
Oxanorbornadiene functionalised galacturonic acid (14). 13a
(50 mg, 0.21 mmol, 1.0 equiv.) was dissolved in 3 mL of
H2Odist.. Then, diisopropylethylamine (70 μL, 0.42 mmol, 2.0
equiv.) and O-benzotriazole-1-yl-N,N,N′,N′-tetramethyluronium
tetraﬂuoroborate (TBTU, 97 mg, 0.25 mmol, 1.2 equiv.) were
added and the mixture was stirred at room temperature for 1 h.
Afterwards 4 (53 mg, 0.21 mmol, 1.0 equiv.) was added and the
reaction mixture was stirred for another 12 h. The mixture was
lyophilised and puriﬁed by preparative HPLC. (C18-P[A])
(H2O–MeOH 95 : 5 → 90 : 10 {5 min}, 90 : 10 → 60 : 40
{55 min}, 60 : 40 → 30 : 70 {30 min}, 30 : 70 → 0 : 100
{10 min}, 15 mL min−1). Compound 14 was collected at a reten-
tion time of tR = 68–72 min as a colourless waxy solid (9.8 mg,
21.12 μmol, 10%). δH (400 MHz, D2O) 7.37–7.32 (m, 2H),
6.03–5.92 (m, 1H), 5.85–5.84 (m, 1H), 5.72–5.71 (m, 1H),
5.40–5.27 (m, 2H), 4.47 (d, J 7.4, 1H), 4.44–4.36 (m, 1H),
4.23–4.15 (m, 1H), 4.21 (d, J 1.4, 1H), 3.72–3.68 (m, 1H),
3.60–3.58 (m, 1H), 3.56–3.52 (m, 2H), 3.47–3.32 (m, 2H); δC
(100 MHz, D2O) 170.9, 170.6, 142.9, 142.9, 142.8, 142.7,
133.1, 118.8, 101.3, 85.5, 83.0, 74.5, 72.4, 70.5, 70.1, 69.0,
38.5, 38.2; MS (ESI+): m/z 465.15 [M + H]+, calcd for
C19H23N2O8F3 465.15.
5-Azidovaleric acid conjugated to oxanorbornadiene functio-
nalised galacturonic acid (15a + 15b). 14 (5 mg, 0.011 mmol,
1.0 equiv.) and 5-azido-valeric acid 6 (2.5 μL, 0.016 mmol,
1.5 equiv.) were dissolved in 1 mL of water. The reaction
mixture was stirred at room temperature for 2 days and lyophi-
lised. The solid was puriﬁed and separated by semipreparative
HPLC (C18-P[A]; 1% aqueous ammonium acetate–MeOH
90 : 10 {80 min}, 50 : 50 {20 min}, 0 : 100 {10 min}). Regio-
isomer 15a was collected at a retention time of tR = 51.17 min,
while regioisomer 15b was collected at a retention time of tR =
55.65 min. Both products are colourless creamy solids (15a:
1.1 mg, 2.0 μmol, 19%; 15b: 0.9 mg, 1.7 μmol, 15%).
δH (400 MHz, D2O) 5.90–5.82 (m, 1H), 5.22 (dd, J 17.3, J 1.4,
1H), 5.16 (dd, J 10.5, J 0.7, 1H), 4.60 (t, J 7.2, 2H), 4.41 (d,
J 7.9, 1H), 4.28–4.24 (m, 1H), 4.15 (dd, J 3.6, J 1.0, 1H), 4.13
(d, J 1.1, 1H), 4.11–4.07 (m, 1H), 3.64 (dd, J 9.8, J 3.4, 1H),
3.60–3.56 (m, 2H), 3.54 (dd, J 9.7, J 8.1, 1H), 3.40–3.35 (m,
2H), 2.24 (t, J 7.4, 2H), 1.90 (q, J 8.1, 2H), 1.54 (q, J 7.6, 2H);
δC (100 MHz, D2O) 180.9, 170.5, 160.9, 141.4, 133.0, 126.9
(q, JC,F 42.8), 118.9 (q, JC,F 269.6), 118.8, 101.3, 74.6, 72.3,
70.5, 70.1, 68.9, 51.3, 38.4, 38.3, 35.1, 28.7, 22.1; δF
(600 MHz, D2O) −56.3; MS (ESI+): m/z 540.19 [M + H]+, calcd
for C20H29N5O9F3 540.19 (15a). δH (400 MHz, D2O) 5.93–5.86
(m, 1H), 5.25 (dd, J 17.2, J 1.5, 1H), 5.19 (dd, J 10.5, J 1.1,
1H), 4.49 (t, J 6.9, 2H), 4.45 (d, J 7.9, 1H), 4.36–4.32 (m, 1H),
4.17–4.12 (m, 1H), 4.15 (dd, J 3.6, J 1.0, 1H), 4.13 (d, J 1.0,
1H), 3.66 (dd, J 10.9, J 3.1, 1H), 3.60–3.55 (m, 2H), 3.49 (dd,
J 9.8, J 8.0, 1H), 3.39–3.33 (m, 2H), 2.18 (t, J 7.4, 2H), 1.85 (q,
J 7.2, 2H), 1.45 (q, J 7.8, 2H); δC (100 MHz, D2O) 181.4,
170.5, 158.9, 135.2 (q, JC,F 39.4), 133.0, 131,7, 119.7 (q,
JC,F 268.6), 118.6, 101.3, 74.5, 72.3, 70.5, 70.1, 69.1, 49.9,
38.8, 38.3, 35.7, 28.7, 22.1; δF (600 MHz, D2O) −59.3;
MS (ESI+): m/z 540.19 [M + H]+, calcd for C20H29N5O9F3
540.19 (15b).
4-Triﬂuoromethylfuran-3-carboxylic acid (19). 3-(Triﬂuoro-
methyl)-4-ethoxycarbonylfuran 18 was prepared according to
Nezis et al.18 18 (30.0 mg, 0.15 mmol, 1.0 equiv.) was dissolved
in 500 μLTHF, and 200 μL LiOHaq (1 M) was added. The reac-
tion mixture was stirred over night at room temperature and
extracted with ethyl acetate. HClaq (1 M) was added to the
aqueous phase until a pH of 2 was reached. The aqueous phase
was extracted with diethyl ether, the combined organic layers
















































were dried over MgSO4 and the solvent was evaporated under
reduced pressure. Compound 19 was obtained as a colourless
solid (11.8 mg, 65.6 μmol, 47%). Mp: 118 °C; δH (400 MHz,
CDCl3) 8.18 (s, 1H), 7.84 (s, 1H); δC (100 MHz, CDCl3) 165.9,
151.8, 145.2 (q, JC,F 6.5), 125.3, 121.3 (q, JC,F 267.3), 116.6
(q, JC,F 38.8); δF (600 MHz, D2O) −58.7; MS (ESI−): m/z
178.99 [M − H]−, calcd for C6H2F3O3 178.99.
tert-Butyl (2-(4-(triﬂuoromethyl)furan-3-carboxamido)ethyl)
carbamate (19a). 19 (15.0 mg, 0.083 mmol, 1.0 equiv.) and
N-Boc-ethylendiamine (15 μL, 0.094 mmol, 1.2 equiv.) were
dissolved in DMF (2 mL). DIPEA (30 μL, 0.182 mmol,
2.2 equiv.) and (7-azabenzotriazole-1-yloxy) tripyrrolidino-phos-
phonium hexaﬂuorophosphate (PyAOP, 85 mg, 0.163 mmol,
2.0 equiv.) were added and the resulting reaction mixture was
stirred for 12 h. The solvent was removed under reduced
pressure, the crude product was dissolved in ethyl acetate,
washed with water, the layers were separated and the organic
layer was dried over MgSO4. Ethyl acetate was removed under
reduced pressure until an oily residue was obtained. After puriﬁ-
cation by column chromatography (ethyl acetate), followed by
recrystallisation in chloroform, 19a was isolated as a colourless
solid (22.5 mg, 69.9 μmol, 84%). Mp: 130 °C; Rf = 0.8
(EtOAc); δH (400 MHz, CDCl3) 7.93 (s, 1H), 7.78 (s, 1H), 6.88
(bs, 1H), 4.99 (bs, 1H), 3.51 (q, J 5.5, 2H), 3.35 (q, J 5.5, 2H),
1.41 (s, 9H); δC (100 MHz, CDCl3) 160.8, 157.3, 146.7, 144.5
(q, JC,F 6.5), 123.2 (q, JC,F 267.3), 120.1, 115.9 (q, JC,F 34.8),
79.9, 41.3, 39.9, 28.3; δF (600 MHz, CDCl3) −58.4; MS (ESI+):
m/z 345.10 [M + Na]+, calcd for C13H17N2O4F3Na 345.10.
N-(2-Aminoethyl)-4-(triﬂuoromethyl)furan-3-carboxamide (20).
t-Butyl {2-[4-(triﬂuoromethyl) furan-3-carboxamido]ethyl} car-
bamate 19a (5 mg, 0.016 mmol, 1 equiv.) was dissolved in
CH2Cl2 (2 mL). Triﬂuoroacetic acid (TFA, 12 μL, 0.155 mmol,
10 equiv.) was added and the resulting mixture was stirred for
2 h at room temperature. All solvents as well as TFA were
removed under reduced pressure by azeotropic distillation with
toluene (3 mL). After drying at <0.1 mbar 20 was obtained as a
colourless solid (2.2 mg, 9.9 μmol, 64%). Mp: 65 °C;
δH (400 MHz, CDCl3) 8.11–8.10 (m, 1H), 8.08–8.07 (m, 1H),
3.64 (q, J 6.0, 2H), 3.35 (q, J 6.0, 2H); δC (100 MHz, CDCl3)
164.3, 146.7, 145.7 (q, JC,F 6.3), 121.8 (q, JC,F 266.3), 118.2,
115.5 (q, JC,F 43.6), 38.9, 36.9; δF (600 MHz, D2O) −59.1; MS
(ESI+): m/z 223.07 [M + H]+, calcd for C8H10N2O2F3 345.10.
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